203 related articles for article (PubMed ID: 25295576)
1. A heterozygous female with Fabry disease due to a novel α-galactosidase A mutation exhibits a unique synaptopodin distribution in vacuolated podocytes.
Takahashi N; Yokoi S; Kasuno K; Kogami A; Tsukimura T; Togawa T; Saito S; Ohno K; Hara M; Kurosawa H; Hirayama Y; Kurose T; Yokoyama Y; Mikami D; Kimura H; Naiki H; Sakuraba H; Iwano M
Clin Nephrol; 2015 May; 83(5):301-8. PubMed ID: 25295576
[TBL] [Abstract][Full Text] [Related]
2. A case of latent heterozygous Fabry disease in a female living kidney donor candidate.
Minami M; Mizuma E; Nakahara M; Oda Y; Yoshimine H; Tokunaga K; Mitsuke A; Yamada Y; Enokida H; Masutani K; Goto N; Ido A
CEN Case Rep; 2021 Feb; 10(1):30-34. PubMed ID: 32712909
[TBL] [Abstract][Full Text] [Related]
3. A case of female Fabry disease revealed by renal biopsy.
Aratani S; Yamakawa H; Suzuki S; Otsuka T; Sakai Y; Shimizu A; Tsuruoka S
CEN Case Rep; 2020 Feb; 9(1):24-29. PubMed ID: 31542871
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical Response to Enzyme Replacement Therapy of Fabry Disease Cardiomyopathy.
Frustaci A; Russo MA; Chimenti C
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27486136
[No Abstract] [Full Text] [Related]
6. Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body.
Oikawa M; Sakamoto N; Kobayashi A; Suzuki S; Yoshihisa A; Yamaki T; Nakazato K; Suzuki H; Saitoh S; Kiko Y; Nakano H; Hayashi T; Kimura A; Takeishi Y
BMC Cardiovasc Disord; 2016 May; 16():83. PubMed ID: 27160240
[TBL] [Abstract][Full Text] [Related]
7. Fabry disease: Review and experience during newborn screening.
Hsu TR; Niu DM
Trends Cardiovasc Med; 2018 May; 28(4):274-281. PubMed ID: 29100912
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.
Chimenti C; Pieroni M; Morgante E; Antuzzi D; Russo A; Russo MA; Maseri A; Frustaci A
Circulation; 2004 Aug; 110(9):1047-53. PubMed ID: 15313943
[TBL] [Abstract][Full Text] [Related]
9. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
[TBL] [Abstract][Full Text] [Related]
10. Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening.
Chen Z; Yin B; Jiao J; Ye T
BMC Nephrol; 2024 Feb; 25(1):61. PubMed ID: 38383316
[TBL] [Abstract][Full Text] [Related]
11. Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease.
Aoyama Y; Ushio Y; Yokoyama T; Taneda S; Makabe S; Nishida M; Manabe S; Sato M; Kataoka H; Tsuchiya K; Nitta K; Mochizuki T
Intern Med; 2020; 59(7):971-976. PubMed ID: 32238663
[TBL] [Abstract][Full Text] [Related]
12. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
[TBL] [Abstract][Full Text] [Related]
13. Kidney transplantation from a mother with unrecognized Fabry disease to her son with low α-galactosidase A activity: A 14-year follow-up without enzyme replacement therapy.
Odani K; Okumi M; Honda K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():57-9. PubMed ID: 26971403
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease previously diagnosed as Henoch-Schonlein purpura.
Kim JH; Han DH; Park MY; Choi SJ; Kim JK; Hwang SD; Jin SY
Korean J Intern Med; 2015 Nov; 30(6):925-7. PubMed ID: 26552470
[No Abstract] [Full Text] [Related]
15. An asymptomatic heterozygous female with fabry disease: implications for enzyme replacement therapy.
Inagaki S; Migita M; Hayakawa M; Fujita A; Yoshida J; Ishizaki M; Kotani M; Sakuraba H; Shimada T; Murakami M; Fukunaga Y
J Nippon Med Sch; 2005 Dec; 72(6):387-90. PubMed ID: 16415520
[TBL] [Abstract][Full Text] [Related]
16. Oligosymptomatic cornea verticillata in a heterozygote for Fabry disease: a novel mutation in the alpha-galactosidase gene.
Kono JO; Podskarbi T; Shin Y; Lanzl I
Cornea; 2003 Mar; 22(2):175-7. PubMed ID: 12605057
[TBL] [Abstract][Full Text] [Related]
17. Autopsy Findings of Heterozygous Fabry Disease with the Severe Phenotype: A Case Report.
Hiratsuka M; Koyama K; Ito M; Sato R; Suzuki K; Ito Y; Namba-Hamano T; Hamano T
Nephron; 2022; 146(2):203-208. PubMed ID: 34808632
[TBL] [Abstract][Full Text] [Related]
18. Anderson-Fabry disease.
Di Toro A; Favalli V; Arbustini E
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e1-e5. PubMed ID: 29538136
[No Abstract] [Full Text] [Related]
19. First phenotypic description of a female patient with c.610 T > C variant of GLA: a renal-predominant presentation of Fabry disease.
Greillier S; Daniel L; Caillaud C; Dussol B; Touchard G; Goujon JM; Jourde-Chiche N; Bobot M
BMC Med Genet; 2020 Jun; 21(1):137. PubMed ID: 32590976
[TBL] [Abstract][Full Text] [Related]
20. A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report.
Pisani A; Imbriaco M; Zizzo C; Albeggiani G; Colomba P; Alessandro R; Iemolo F; Duro G
BMC Cardiovasc Disord; 2012 Jun; 12():39. PubMed ID: 22682330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
